Skip to content
Search

Latest Stories

Aditya Roy Kapur and Sanjana Sanghi starrer OM starts rolling

Murtuza Iqbal

A few weeks ago, it was announced that Aditya Roy Kapur will be seen in an action film titled OM – The Battle Within. Later, the makers had announced that Dil Bechara fame actress Sanjana Sanghi will be seen opposite Aditya in the film.


Today, the shooting of the film has kickstarted, and Ahmed Khan, who is co-producing the movie, took to Twitter to inform everyone about it. He tweeted, “Lights. Camera. Mahurat for #OM: The Battle Within begins! ⭐ing #AdityaRoyKapur and @sanjanasanghi96 , the action thriller is produced by @ZeeStudios_ , @khan_ahmedasas , and @shairaahmedkhan and directed by @itskapilverma ! #Summer2021 #ShootBegins @PaperdollEnt."

OM is co-produced by Zee Studios and it is directed by Kapil Verma. The makers have not yet officially announced the release date, but reportedly, the film will hit the big screens in the second half of 2021.

Aditya Roy Kapur was last seen in Ludo which released on Netflix a few weeks ago. Talking about Sanjana Sanghi, the actress made her debut as a lead in this year’s release Dil Bechara. The film, which was Sushant’s last movie, got a direct-to-digital release on Disney+ Hotstar.

Well, it will be interesting to see this new jodi of Aditya and Sanjana on the big screen in OM.

More For You

Gloabl acquisitions

Indian companies are buying overseas again, but this time the strategy looks different

iStock

Indian companies spent $18+ billion on overseas acquisitions in 2025

  • Indian companies are buying overseas again, but this timethe strategy looks different.
  • Sun Pharmaceutical Industries recently agreed to buy Organon & Co for £8.59 billion ($11.75 billion).
  • Analysts suggest firms are chasing technology, markets and supply chain security rather than global prestige alone.

Indian companies are once again on a global buying spree, snapping up businesses across sectors ranging from pharmaceuticals and automotive to artificial intelligence and insurance. But unlike the headline-grabbing takeover wave of the early 2000s, this new phase appears to be driven less by corporate prestige and more by survival, diversification and access to technology.

The latest example came in late April when Sun Pharmaceutical Industries agreed to acquire New York-listed Organon & Co for £8.59 billion ($11.75 billion), marking the largest overseas acquisition by an Indian company in nearly two decades.

Keep ReadingShow less